Drugs /

spartalizumab

Back to Drugs List

Overview

Generic Name(s):
spartalizumab
NCI Definition [1]:
A humanized monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed death-1 (PD-1, PCD-1), with immune checkpoint inhibitory and antineoplastic activities. Upon administration, spartalizumab binds to PD-1 expressed on activated T-cells and blocks the interaction with its ligands, programmed cell death 1 ligand 1 (PD-L1, PD-1L1) and PD-1 ligand 2 (PD-L2, PD-1L2). The inhibition of ligand binding prevents PD-1-mediated signaling and results in both T-cell activation and the induction of T-cell-mediated immune responses against tumor cells. PD-1, an immunoglobulin (Ig) superfamily transmembrane protein and inhibitory receptor, negatively regulates T-cell activation.

Clinical Trials

View Clinical Trials for spartalizumab

Spartalizumab has been investigated in 47 clinical trials, of which 34 are open and 13 are closed. Of the trials investigating spartalizumab, 2 are early phase 1 (2 open), 23 are phase 1 (16 open), 10 are phase 1/phase 2 (6 open), 11 are phase 2 (9 open), and 1 is phase 3 (1 open).

HER2 Deficient Expression, HER2 Negative, and ER Negative are the most frequent biomarker inclusion criteria for spartalizumab clinical trials.

Breast carcinoma, malignant solid tumor, and non-small cell lung carcinoma are the most common diseases being investigated in spartalizumab clinical trials [2].

Top Biomarker Inclusion Criteria for Open Clinical Trials Investigating Spartalizumab
Top Biomarker Inclusion Criteria for Closed Clinical Trials Investigating Spartalizumab
This graph displays the 20 most frequently occurring biomarkers curated on clinical trials investigating spartalizumab and the cancer types associated with these biomarkers. These numbers are derived from a set of 5,956 clinical trials for which biomarker status defines treatment.

Drug Details

Synonyms [2]:
anti-pd1 monoclonal antibody pdr001, pdr-001, pdr001, anti-pd1 monoclonal antibody pdr001
Drug Target(s) [2]:
PDCD1
NCIT ID [1]:
C121625

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.